(Q53576374)

English

Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer.

scientific article published in September 2006

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

Achieving full-dose, on-schedule administration of ACE chemotherapy every 14 days for the treatment of patients with extensive small-cell lung cancer. (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

1 reference

based on heuristic

inferred from title

author name string

R Pirker

1

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

E Ulsperger

2

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

J Messner

3

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

K Aigner

4

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

B Forstner

5

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

P Bacon

6

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

V Easton

7

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

T Skacel

8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

publication date

1 September 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

184

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

5

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

279-285

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

Randomized multicentre trial of filgrastim as an adjunct to combination chemotherapy for Hodgkin's disease. West of Scotland Lymphoma Group

1 reference

https://api.crossref.org/works/10.1007%2FS00408-005-2594-8

21 January 2018

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Res

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Ran

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The feasibility of using glycosylated recombinant human granulocyte colony-stimulating factor (G-CSF) to increase the planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) in the treatment of small cell lung cancer. Medical Res

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reporting results of cancer treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Small cell lung cancer. State-of-the-art therapy 1994.

1 reference

https://pubmed.ncbi.nlm.nih.gov/17235728

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00408-005-2594-8

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

release_35nwghlgqbgmxfrxrqth5ngxay

1 reference

https://api.fatcat.wiki/v0/release/35nwghlgqbgmxfrxrqth5ngxay

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 May 2018

http://europepmc.org/abstract/MED/17235728

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53576374&oldid=2212212524"